



Pharmicell Co., Ltd.

www.pharmicell.com/eng

Pharmicell Co., Ltd. is a biopharmaceutical company that developed the world's first stem cell therapy (Hearticellgram-AMI) in 2011. The company's business area divided into two sectors as below in detail.

First, in the bio business sector, stem cell R&D for curing obstinate disease and improving human health. Second, the biochemical division develops and produces Raw Material Pharmaceutical Intermediates.

Pharmicell Co., Ltd. will do its best to grow into a respected company for curing obstinate disease and improving human health.

Main Products



CEO
Kim, Hyun Soo

Location
7th floor, Ssangbong Building,
874 Unju-ro, Gangnam-gu,
Seoul-si

Specialty
1. Stem Cell Therapeutics
2. Next Generation Dendritic Cell Therapeutic Vaccines
3. Raw Material Pharmaceutical Intermediates

Tel / Fax / E-mail
T. 82-2-3496-0114
F. 82-2-3496-0159
E. pmc@pharmicell.com

Product (Ingredient/Formulation)	Use	Remarks
Hearticellgram-AMI (Autologous Bone Marrow-Derived Mesenchymal Stem Cell)	Acute Myocardial Infarction	Launched
Cellgram-LC (Autologous Bone Marrow-Derived Mesenchymal Stem Cell)	Alcoholic Liver cirrhosis	Developing (Clinical Trial, Phase II completed)
Cellgram-ED (Autologous Bone Marrow-Derived Mesenchymal Stem Cell)	Erectile Dysfunction	Developing (Clinical Trial, Phase I completed)
Cellgram-DC-OC (Prostate Cancer Ag pulsed Autologous Dendritic Cell)	AnticancerImmuncell Therapeutic Vaccine for Prostate Cancer.	Developing (Clinical Trails)
Cellgram-DC-OC (Ovarian Cancer Ag pulsed Autologous Dendritic Cell)	AnticancerImmuncell Therapeutic Vaccine for Ovarian Cancer.	Developing (Clinical Trails)

R&D Pipeline

